Results 221 to 230 of about 75,041 (254)
Some of the next articles are maybe not open access.
Glucagon-like peptide-1 and glucagon-like peptide-2
Best Practice & Research Clinical Endocrinology & Metabolism, 2004The glucagon-like peptides (glucagon-like peptide-1 (GLP-1) and glucagon-like peptide-2 (GLP-2)) are released from enteroendocrine cells in response to nutrient ingestion. GLP-1 enhances glucose-stimulated insulin secretion and inhibits glucagon secretion, gastric emptying and feeding. GLP-1 also has proliferative, neogenic and antiapoptotic effects on
Laurie L. Baggio, Daniel J. Drucker
openaire +1 more source
Glucagon-like peptide-1 in the pathogenesis of obesity
Drug News & Perspectives, 1998The recently discovered gut peptide glucagon-like peptide-1 (GLP-1) is one of many peptides implicated in the short-term regulation of appetite. GLP-1 is a 30-amino-acid peptide that is produced in and secreted from the L cells of the intestinal mucosa after intake of a mixed meal.
E, Näslund, P M, Hellström
openaire +2 more sources
Glucagon-like peptide 1 in health and disease
Nature Reviews Endocrinology, 2018In healthy individuals, the incretin hormone glucagon-like peptide 1 (GLP1) potentiates insulin release and suppresses glucagon secretion in response to the ingestion of nutrients. GLP1 also delays gastric emptying and increases satiety. In patients with type 2 diabetes mellitus (T2DM), supraphysiological doses of GLP1 normalize the endogenous insulin ...
Andreas Andersen +3 more
openaire +3 more sources
Glucagon-like Peptide-1 and Islet Lipolysis
Hormone and Metabolic Research, 2004A role for glucagon-like peptide 1 (GLP-1) has been suggested in stimulating beta-cell lipolysis via elevation of cAMP and activation of protein kinase A, which in turn may activate hormone-sensitive lipase (HSL), thereby contributing to fatty acid generation (FFA) from intracellular triglyceride stores.
M, Sörhede Winzell, B, Ahrén
openaire +2 more sources
Glucagon-Like Peptide 1—A Cardiologic Dimension
Trends in Cardiovascular Medicine, 2010Recent experimental data suggest glucagon-like peptide 1 (GLP-1) and its analogs to have direct effects on the cardiovascular system, in addition to their classic glucoregulatory actions. These direct effects may be cardioprotective, contractility augmenting, and vasorelaxant.
Treiman, Marek +3 more
openaire +3 more sources
Glucagon-like peptide-1 receptor
Current BiologyMichael Krashes discusses glucagon-like peptide-1 receptors, their physiological role in glucose metabolism and the mode of action of their agonists that are used to treat obesity and were later shown to promote weight loss.
openaire +2 more sources
Glucagon-Like Peptide 1 and the Cardiovascular System
Current Diabetes Reviews, 2014Glucagon-like peptide 1 (GLP1) is a major incretin hormone. This means that it is secreted by the gut in response to food and helps in reducing post-prandial glucose exertion. It achieves this through a number of mechanisms, including stimulating insulin release by pancreatic β-cells in a glucose-dependent manner; inhibition of glucagon release by ...
openaire +2 more sources
Glucagon-like peptide-1 medicines and cancer
Nature CancerGlucagon-like peptide-1 (GLP-1) medicines reduce food intake, body weight, insulin resistance and inflammation, thus improving outcomes for people with type 2 diabetes and obesity and potentially contributing to decreased cancer incidence. GLP-1 medicines acting through weight loss-dependent and weight loss-independent mechanisms hold potential for ...
Julian M. Yabut, Daniel J. Drucker
openaire +2 more sources
Glucagon and Glucagon-Like Peptides 1 and 2
2009The glucagon gene is expressed not only in the alpha cells of the pancreatic islets but also in the endocrine cells of the intestinal epithelium (so-called L-cells), and in certain neurons of the brain stem. Whereas in the pancreas, glucagon, the hyperglycaemic hormone, is cleaved out of the 160 amino acid precursor, proglucagon, leaving behind ...
openaire +3 more sources